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Aggregatibacter Actinomycetemcomitans Leukotoxin Utilizes a Cholesterol
Recognition/Amino Acid Consensus Site for Membrane Association
Abstract
Aggregatibacter actinomycetemcomitans produces a repeats-in-toxin (RTX) leukotoxin (LtxA) that
selectively kills human immune cells. Binding of LtxA to its β2 integrin receptor (lymphocyte functionassociated antigen-1 (LFA-1)) results in the clustering of the toxin·receptor complex in lipid rafts.
Clustering occurs only in the presence of LFA-1 and cholesterol, and LtxA is unable to kill cells lacking
either LFA-1 or cholesterol. Here, the interaction of LtxA with cholesterol was measured using surface
plasmon resonance and differential scanning calorimetry. The binding of LtxA to phospholipid bilayers
increased by 4 orders of magnitude in the presence of 40% cholesterol relative to the absence of
cholesterol. The affinity was specific to cholesterol and required an intact secondary structure. LtxA
contains two cholesterol recognition/amino acid consensus (CRAC) sites; CRAC336 (333LEEYSKR339) is
highly conserved among RTX toxins, whereas CRAC503 (501VDYLK505) is unique to LtxA. A peptide
corresponding to CRAC336 inhibited the ability of LtxA to kill Jurkat (Jn.9) cells. Although peptides
corresponding to both CRAC336 and CRAC503 bind cholesterol, only CRAC336 competitively inhibited LtxA
binding to this sterol. A panel of full-length LtxA CRAC mutants demonstrated that an intact CRAC336 site
was essential for LtxA cytotoxicity. The conservation of CRAC336 among RTX toxins suggests that this
mechanism may be conserved among RTX toxins.
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Background: A repeats-in-toxin (RTX) leukotoxin and its integrin receptor aggregate in cholesterol-rich lipid rafts.
Results: The affinity of the toxin to cholesterol is driven by a cholesterol recognition/amino acid consensus (CRAC) motif.
Conclusion: Leukotoxin cytotoxicity is regulated by the CRAC motif.
Significance: Other RTX toxins contain this CRAC motif, suggesting a role for cholesterol recognition in RTX cytolysis.
Aggregatibacter actinomycetemcomitans produces a repeatsin-toxin (RTX) leukotoxin (LtxA) that selectively kills human
immune cells. Binding of LtxA to its ␤2 integrin receptor (lymphocyte function-associated antigen-1 (LFA-1)) results in the
clustering of the toxin䡠receptor complex in lipid rafts. Clustering occurs only in the presence of LFA-1 and cholesterol, and
LtxA is unable to kill cells lacking either LFA-1 or cholesterol.
Here, the interaction of LtxA with cholesterol was measured
using surface plasmon resonance and differential scanning calorimetry. The binding of LtxA to phospholipid bilayers
increased by 4 orders of magnitude in the presence of 40% cholesterol relative to the absence of cholesterol. The affinity was
specific to cholesterol and required an intact secondary structure. LtxA contains two cholesterol recognition/amino acid
consensus (CRAC) sites; CRAC336 (333LEEYSKR339) is highly
conserved among RTX toxins, whereas CRAC503 (501VDYLK505)
is unique to LtxA. A peptide corresponding to CRAC336 inhibited the ability of LtxA to kill Jurkat (Jn.9) cells. Although peptides corresponding to both CRAC336 and CRAC503 bind cholesterol, only CRAC336 competitively inhibited LtxA binding to
this sterol. A panel of full-length LtxA CRAC mutants demonstrated that an intact CRAC336 site was essential for LtxA cytotoxicity. The conservation of CRAC336 among RTX toxins suggests that this mechanism may be conserved among RTX toxins.

Aggregatibacter actinomycetemcomitans is a pioneer colonizer of the upper aerodigestive tract of man. In the establishment of the ecological niche of the organism, it relies upon an
array of virulence determinants, one of which is a leukotoxin
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(LtxA) that selectively kills human immune cells (1) in a process
that is initiated by recognition of a cell surface molecule that
leads to a multistep cascade and results in targeted cell death
(2). LtxA is a member of the repeats-in-toxin (RTX)2 family of
cytotoxic proteins (3), which share cell type specificity that is
driven by their association with ␤2 integrin heterodimers, such
as lymphocyte-function associated antigen-1 (LFA-1) (4) and
macrophage-1 antigen (Mac-1)/complement receptor 3 (CR3)
(5).
Five genes are required for successful translation and secretion of LtxA (the structural toxin gene product) in A. actinomycetemcomitans. Four of the genes, ltxCABD (in transcriptional
order) are located in the leukotoxin operon. A fifth gene, tdeA
(6), is not part of the ltx operon and is located 572 kb downstream of this site. Prior to secretion, Gram-negative bacterial
protein toxins are translated as protoxins and must be posttranslationally modified to achieve biological activity. This
modification takes various forms with bacterial protein toxins.
In the case of RTX toxins, the RTXC protein, an acylase, catalyzes the attachment of fatty acyl chains to internal lysine residues of the toxin (7–9) in the bacterial cytoplasm; this acylation
process is necessary for the toxin to achieve its biological activity (10). The remaining three gene products (LtxB, LtxD, and
TdeA) form a type I secretion system and export LtxA directly
from the bacterial cytoplasm to the external environment without the need for a periplasmic intermediate.
Hydropathy analysis of the amino acid sequence of LtxA
(114.5 kDa; 1055 amino acids) (35, 36) in combination with
algorithms predicting secondary structure (37, 38) permit the
division of LtxA into four domains: hydrophobic, central,
repeat, and C-terminal domains (35, 36) (Fig. 1A). The hydrophobic domain (residues 1– 420) contains a preponderance of

2

The abbreviations used are: RTX, repeats-in-toxin; LFA-1, lymphocyte
function-associated antigen-1; CRAC, cholesterol recognition/amino
acid consensus; SPR, surface plasmon resonance; DSC, differential scanning calorimetry; DMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholine;
SOPC, 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine; DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine; GuHCl, guanidine hydrochloride.
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TABLE 1
Cytotoxicity of LtxA and Acylation Mutants
LtxAwt, LtxArenatured, LtxACS001 (nonacylated), and LtxASM003 (acylated) were incubated with Jn.9 cells. Cytotoxicity was measured using a trypan blue assay and was
calculated as the number of cells killed relative to an untreated control. Each value
represents the mean of three experiments ⫾ standard deviation.
Protein

Cytotoxicity
% untreated control

0.77 ⫾ 0.08
0.20 ⫾ 0.15
0.31 ⫾ 0.24
0.54 ⫾ 0.08

LtxAwt
LtxArenatured
LtxACS001
LtxASM003

FIGURE 1. Structure and purity of LtxA. A, the sequence of LtxA contains an
N-terminal hydrophobic domain, a central domain that contains two internal
lysines (red circle labeled A) that are the sites of acylation, a repeat domain,
and a C-terminal domain. The CRAC sites identified in this work are located
near the hydrophobic region (yellow circle labeled C). B, SDS-PAGE gel and
Western blot of LtxAwt, LtxACS001, and LtxASM003.

hydrophobic amino acids and suggests an involvement in membrane insertion. Secondary structure predictions of the region
show that half of the residues form either amphipathic or
hydrophobic ␣-helices, which are often associated with toxintarget cell membrane interactions. Comparison of the amino
acid sequence of LtxA with other RTX toxins, such as Escherichia coli ␣-hemolysin (HlyA) and Mannheimia hemolytica
LktA, show a remarkable concordance in the clustering of
hydrophobic and hydrophilic residues among the three toxins
in this area (35, 36). The central domain (residues 421–730) is
composed largely of hydrophilic residues, and the conservation
of structure among the various RTX toxins is less strong.
Located within the central region are the two acylated lysine
residues (Lys562 and Lys687) that are necessary for biological
activity (10) (Fig. 1A, red circles labeled A). The repeat region
(residues 730 –900) contains a series of 14 repeated nonapeptides with the consensus sequence of GGXG(N/D)DX(L/I/F)X
(where X represents any amino acid), which together form a
unique calcium-binding structure that is called a parallel ␤-helix or parallel ␤-roll (39, 40). LtxA has been shown to bind
calcium as well (41). Finally the C-terminal domain (positions
901–1055) is required for secretion (42).
The RTX toxins are known to be secreted into the aqueous
solution but also to be membrane-interacting proteins (11).
Neither the water-soluble nor the membrane-embedded structures of these toxins (and LtxA in particular) have been solved;
however, it has been proposed that this family of toxins undergoes a conformational change upon membrane association
(12). We have recently shown that LtxA undergoes distinct
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lipid-specific secondary structure changes upon binding to or
disruption of lipid bilayers (13).
LtxA and other RTX toxins bind to various ␤2 integrins and
cluster in lipid rafts (14 –16). The result of this interaction mimics aspects of the integrin (17) activation signal, including the
elevation of cytosolic Ca2⫹, activation of calpain, and cleavage
of talin. The cleavage of talin frees LFA-1 from the cytoskeleton
and allows lateral movement of the LFA-1䡠LtxA complex to
lipid rafts (14). Although talin cleavage and release of LFA-1 is
the initial step in toxin/integrin-driven raft clustering, the process that moves the LtxA䡠LFA-1 complex to the raft and subsequently maintains them in the raft is not clear. This observation
has led us to hypothesize that LtxA has an affinity for cholesterol, a primary raft component, and this interaction may be
responsible for the LtxA䡠LFA-1 clustering observed in intoxicated cells.

EXPERIMENTAL PROCEDURES
Chemicals—NaCl, CaCl2, NaN3, HEPES, cholesterol, guanidine hydrochloride (GuHCl), and KH2PO4 were purchased
from Sigma. Lipids, including 1,2-dimyristoyl-sn-glycero-3phosphocholine (DMPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), and 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), were purchased from Avanti Polar Lipids
(Alabaster, AL). Ergosterol was purchased from MP Biomedicals (Solon, OH). Peptides were synthesized and purified (98%
purity) by Biomatik (Wilmington, DE).
Bacterial Strains, Growth Conditions, and Plasmids—Three
A. actinomycetemcomitans strains were used in this work,
JP2, CS001, and SM003 (18). JP2 produces a wild type LtxA
(LtxAwt), CS001 lacks the ltxC gene and therefore produces an
unacylated LtxA (LtxACS001), and SM003 has been complemented with the ltxC gene in trans and produces an acylated
LtxA (LtxASM003). The A. actinomycetemcomitans strains were
grown overnight in AAGM broth (19) supplemented with antibiotics (JP2: 12.5 g/ml vancomycin and 75 g/ml bacitracin,
CS001: 40 g/ml kanamycin, SM003: 40 g/ml kanamycin and
2 g/ml chloramphenicol). LtxA was purified as described previously (20). The purity of the toxin was confirmed by Coomassie staining of SDS-PAGE and the specificity by crossreactivity with anti-LtxA antibody (Western blot). We
confirmed the activity using a cytotoxicity assay. The purity
of the three proteins is shown in Fig. 1B, and the cytotoxicity
is shown in Table 1.
Production of CRAC mutant LtxA was accomplished in
E. coli using a pSHH plasmid, a pUC19-based plasmid containVOLUME 288 • NUMBER 32 • AUGUST 9, 2013
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TABLE 2
Primers used for site-directed mutagenesis of ltxA
The substituted nucleotides are in bold type.
Primer

Sequence

ltxA_1012_FW
ltxA_1012_RV
ltxA_1513_FW
ltxA_1513_RV

5⬘-AGAATGCTTGAGGAACCCTCGAAACGCTTTAA-3⬘
5⬘-TTAAAGCGTTTCGAGGGTTCCTCAAGCATTCT-3⬘
5⬘-AAAGCTTATGTGGATCCTTTGAAAAAGGGTGA-3⬘
5⬘-TCACCCTTTTTCAAAGGATCCACATAAGCTTT-3⬘

ing the ltxA promoter, ltxC, and ltxA (21). Active LtxA is constitutively expressed in the cytosol.
The CRAC mutants were constructed by substituting proline
for tyrosine at amino acid positions 336 (for CRACY336P) or 503
(for CRACY503P) of ltxA. Site-directed mutagenesis was performed using a QuikChange® site-directed mutagenesis kit
(Agilent Technologies, Inc., Santa Clara, CA), according to the
manufacturer’s instructions. The primers containing substitutions were designed using the OligoPerfectTM Designer as
shown in Table 2. The reactions were performed on an automated thermal cycler with an initial step of 30 s at 95 °C, followed by PCR amplification for 16 cycles of 30 s at 95 °C, 1 min
at 55 °C, and 3 min at 68 °C. The obtained PCR products were
transformed into DH5␣-T1 cells, and the mutant clones were
selected on LB agar plates with 50 g/ml of ampicillin.
CRACY336P and CRACY503P were produced from E. coli
using the following procedure. Overnight cultures of E. coli
DH5␣-T1 containing the plasmid were used at a 1:50 dilution to
inoculate 200 ml of LB/ampicillin (50 g/ml), which was grown
to an A600 of ⬃0.4. The cultures were centrifuged and resuspended in 6 ml of buffer (20 mM Tris-HCl, 250 mM NaCl, 0.2
mM CaCl2, pH 6.8), sonicated (six times for 45 s, on ice), and
centrifuged to remove cell debris (12,000 ⫻ g, 15 min, 4 °C).
LtxA (LtxArenatured) was denatured by incubating 1 M
LtxAwt with an equal volume of 16 M GuHCl overnight (12).
Following incubation, the GuHCl was exchanged with liposome buffer (150 mM NaCl, 5 mM CaCl2, 5 mM HEPES, and 3
mM NaN3, pH 7.4) for use in the SPR experiments.
Cell Culture—Jn.9, a subclone of the Jurkat cell line (22), a gift
from Dr. Lloyd Klickstein (Novartis Institute for Biomedical
Research, Cambridge, MA), was maintained as described previously (14) with 2 mM L-glutamine and 50 g/ml gentamicin.
Liposome Preparation—Lipids dissolved in chloroform were
added to a glass vial in the required amounts (24). The chloroform was evaporated under a stream of nitrogen, and the residual chloroform was removed under vacuum, creating a thin
lipid film on the glass surface. Liposomes were created by
hydrating the lipid film with liposome buffer (150 mM NaCl, 5
mM CaCl2, 5 mM HEPES, 3 mM NaN3, pH 7.4). Large unilamellar vesicles were formed by extruding the liposome solutions
through a 200-nm polycarbonate membrane (24, 25).
The lipid compositions used in this work were chosen based
on their raft-like nature (26). The liposomes were composed of
DMPC with 0, 20, 40, or 60% cholesterol (or ergosterol). At
room temperature, DMPC with 0% cholesterol exists in a nonraft-like state (liquid disordered); at 40 and 60% cholesterol,
DMPC exists in a raft-like state (liquid ordered); and at 20%
cholesterol, both phases coexist (27, 28).
Circular Dichroism Spectroscopy—The extent of unfolding of
LtxArenatured was determined using CD spectroscopy. Three
AUGUST 9, 2013 • VOLUME 288 • NUMBER 32

Mutation site
CRAC336
CRAC336
CRAC503
CRAC503

LtxA samples were prepared at a concentration of 7 M. 1)
Native LtxAwt was suspended in liposome buffer, 2) LtxAdenatured
was prepared as described above (12) and left in GuHCl, and
3) LtxArenatured was prepared as described above, and the buffer
was exchanged with liposome buffer (to recreate the conditions
of the SPR experiment).
CD spectroscopy analysis was performed on a Jasco J-810
spectropolarimeter, as discussed in our previous studies (13).
The samples were analyzed at 25 °C in a 0.2-mm-path length
quartz cell using the step-scanning mode from 260 to 200 nm,
with a 1-nm wavelength step, 10-s averaging time, and 1-nm
bandwidth. The spectra were recorded under identical conditions for an n ⫽ 3 for each sample.
Surface Plasmon Resonance—Liposomes were tethered to an
L1 Biacore chip by flowing them over the chip at a rate of 5
l/min, until a mass corresponding to ⬃1000 response units
(⬃5 l) had been added to the surface (30). A small volume of
NaOH (5 l) was added to remove unbound liposomes.
For kinetic analysis, the flow rate was increased to 30 l/min
before the toxin injection was initiated. Each toxin injection
was 60 l, followed by a 180-l dissociation of buffer only. The
surface was regenerated with an injection of 65 l of 0.5% SDS.
The 10 toxin concentrations ranged from 0 to 500 nM in a 1:2
dilution series. All SPR measurements were performed on a
Biacore威 3000, and the data were evaluated using the BIAevaluation威 software. The data were fit using a 1:1 Langmuir binding
model to obtain the equilibrium dissociation constant (KD), as
well as the association (ka) and dissociation (kd) rates, where KD
is given by the following equation.
KD ⫽

kd
ka

(Eq. 1)

For steady state competition analysis, liposomes containing
40% cholesterol were tethered to an L1 chip. The flow rate was
set at 5 l/min, and 50 l of toxin was injected, followed by a
25-l dissociation of buffer only. The surface was regenerated
with SDS, as described above. In the CRAC peptide competition experiments, the toxin, at a concentration of 1000 nM, was
incubated with an equal volume of peptide at concentrations of
0, 500, 1000, 2000, and 4000 nM (molar LtxA:peptide ratios of
1:0, 1:0.5, 1:1, 1:2, and 1:4). The inhibition was defined as
follows,
%Inhibition ⫽

RULtxA/peptide
⫻ 100
RULtxA

(Eq. 2)

where RLtxA is the response units of the LtxA-only run, and
RULtxA/peptide is the response units of each run containing LtxA
and peptide. Response units represent the surface coverage.
The response units were measured at the end of the injection,
JOURNAL OF BIOLOGICAL CHEMISTRY
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just before the dissociation was initiated, at the same time point
for each experiment. In the comparison of binding to cholesterol-containing liposomes by the acylation mutant toxins,
LtxACS001 and LtxASM003, at concentrations of 250 nM, were
injected over liposomes containing 40% cholesterol that had
been tethered to the L1 chip.
Differential Scanning Calorimetry—The DSC experiments
were performed as described previously (31), with the following
modifications. Approximately 1 mg of the dried peptide was
resuspended in 100 l of methanol and added to a solution of
SOPC with or without cholesterol in chloroform:methanol
(2:1) to give the desired final ratio of peptide to lipids. The
solvent was removed under nitrogen gas, and the final traces of
solvent were removed in a vacuum desiccator. The films were
hydrated with PIPES buffer (20 mM PIPES, 140 mM NaCl, 1 mM
EDTA, adjusted to pH 7.4) and vortexed extensively. The suspension was degassed and loaded into the sample cell of a Nano
II differential scanning calorimeter (Calorimeter Sciences
Corp., Lindon, UT). Buffer was placed in the reference cell.
Successive heating and cooling scans were run between 0 and
45 °C, at a scan rate of 1°/min.
Cytotoxicity—A trypan blue cytotoxicity assay was used to
measure cell viability (32). The percentage of cells killed by each
treatment was calculated by the following,
%kill ⫽

#t ⫽ 0 ⫺ #t ⫽ 5
#t ⫽ 0

(Eq. 3)

where #t⫽0 is the number of cells before treatment, and #t⫽5 is
the number of cells after treatment. Each %kill value was normalized to the %kill value of LtxA alone.
The effect of the CRAC peptides on LtxA-mediated cell
death was measured in cytotoxicity assays, as described previously (14). Briefly, Jn.9 cells were incubated with protein samples containing (a) LtxA (1 ⫻ 10⫺8 M), (b) LtxA (1 ⫻ 10⫺8 M) ⫹
peptide (1 ⫻ 10⫺8 M), or (c) peptide (1 ⫻ 10⫺8 M). The samples
were incubated at 37 °C for 5–24 h.
In the case of the full-length LtxA CRAC mutants, 50 g of
total protein in the E. coli cytosolic fraction was added to 0.5 ⫻
106 Jn.9 cells and incubated for 24 h. Cell death was measured
with a trypan blue assay using a Vi-cell machine (Beckman
Coulter, Hialeah, FL). Western blot analysis was used to confirm LtxA expression. An E. coli DH5␣-T1 cytosolic fraction
that did not contain pSHH served as a control.
Statistical Analysis—The statistical analyses were performed
using either Student’s t test or one-way analysis of variance
using SigmaPlot® (Systat Software, Inc. Chicago, IL). The following statistical criteria were applied: p ⬍ 0.001, p ⬍ 0.05, and
p ⬍ 0.01.

RESULTS
LtxA Has a Strong Affinity for Cholesterol—Fig. 2 shows the
affinity of LtxA for liposomes containing DMPC and varying
amounts of cholesterol (reported as mol %). Using SPR, we
measured the binding of LtxA to membranes containing 0, 20,
40, or 60% cholesterol as a function of time (Fig. 2, A, B, C, and
D, respectively).
These SPR sensorgrams were used to calculate the kinetic
parameters of binding. The affinity of LtxA for the membranes
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increased (KD decreased) as the amount of cholesterol
increased up to 40% and then decreased (KD increased) in membranes containing 60% cholesterol (Fig. 2E). The maximal affinity (minimal KD) to membranes containing 40% cholesterol was
approximately 4 orders of magnitude greater (10⫺12 M) than the
affinity for cholesterol-free membranes (10⫺8 M).
Table 3 shows the corresponding association (ka) and dissociation (kd) rates for the binding of LtxA to liposomes containing 0 – 60% cholesterol. There was no significant change in the
association rate as the amount of cholesterol increased; however, the dissociation rate decreased as the amount of cholesterol in the membranes increased to 40% and then increased at
60% cholesterol. Therefore, the affinity of LtxA to cholesterol,
as measured by the KD, is almost entirely due to cholesterol-dependent changes in the dissociation rate rather than changes in
the association rate.
Binding Is Specific for Cholesterol—We then compared the
affinity of LtxA for liposomes composed of DMPC and varying
amounts of the sterol ergosterol (substituted for cholesterol) as
a specificity control. The structures of these two sterols are
similar, with ergosterol containing an additional double bond
in the B ring and a double bond on carbon 22. The SPR sensorgrams showing LtxA association to and dissociation from
membranes containing 0, 20, 40, and 60% ergosterol are shown
in Fig. 2 (F, G, H, and I, respectively).
As shown in Fig. 2J, the KD values remained essentially constant as the ergosterol composition increased, with no strong
affinity observed at high sterol compositions. In Fig. 2, the difference between panels E and J indicates that the strong affinity
of LtxA to sterol-containing membranes is specific for cholesterol. Membranes composed of DMPC and cholesterol are
known to phase separate into cholesterol-poor (liquid-disordered) and cholesterol-rich (liquid-ordered) regions, depending on the temperature and cholesterol composition of the system (28). The liquid-ordered phase is often used as a model of
lipid rafts because of their similar compositions (rich in cholesterol and saturated lipids, poor in unsaturated lipids).
To determine whether the affinity of LtxA for cholesterolcontaining membranes is determined by the cholesterol composition or by the raft-like nature of the membrane, we compared the affinity of LtxA for membranes composed of 60%
DOPC (unsaturated)/40% cholesterol, a lipid composition that
is liquid-disordered (non-raft-like), with membranes composed of 60% DMPC (saturated)/40% cholesterol, a lipid composition that is liquid-ordered (raft-like). The SPR sensorgrams
showing LtxA association to and dissociation from membranes
containing DMPC/40% cholesterol or DOPC/40% cholesterol
are shown in Fig. 2 (K and L, respectively). The affinity of LtxA
for membranes containing 40% cholesterol was not significantly different for the two lipid types (Fig. 2 M), demonstrating
that it is the presence of cholesterol that regulates this strong
affinity rather than the raft-like nature of the membrane.
To determine whether a specific LtxA structural element
regulates the affinity of the toxin for cholesterol, we studied the
binding of renatured LtxA (LtxArenatured) to DMPC membranes containing varying amounts of cholesterol. The binding
of LtxArenatured to membranes containing 0, 20, 40, or 60% cholesterol as a function of time is shown in Fig. 3 (A, B, C, and D,
VOLUME 288 • NUMBER 32 • AUGUST 9, 2013
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FIGURE 2. Affinity of LtxAwt for sterol-containing membranes. Liposomes containing 0, 20, 40, or 60% sterol were tethered to an L1 Biacore chip, and LtxAwt
was injected over the top. A–D, The sensorgrams show LtxAwt binding to membranes containing 0% cholesterol (A), 20% cholesterol (B), 40% cholesterol (C),
and 60% cholesterol (D). E, the binding affinity (KD) of LtxAwt for cholesterol was calculated from these sensorgrams. A one-way analysis of variance test
demonstrated that the data in E are significant (p ⬍ 0.05). F–I, a second series of sensorgrams shows the binding of LtxA to membranes containing 0%
ergosterol (F), 20% ergosterol (G), 40% ergosterol (H), and 60% ergosterol (I). J, the binding affinity (KD) of LtxA for ergosterol was calculated from these
sensorgrams. A one-way analysis of variance test indicates that there is no significant difference in the data (p ⫽ 0.097). K and L, the third set of sensorgrams
shows the binding of LtxAwt to membranes containing DMPC/40% cholesterol (K) and DOPC/40% cholesterol (L). M, the affinity of LtxAwt for liposomes
containing 40% cholesterol and either the saturated lipid, DMPC, or the unsaturated lipid, DOPC, is not significantly different (p ⫽ 0.207). These two lipid
systems contain the same amount of cholesterol but differ in their raft-like nature, with DMPC/40% cholesterol existing in a raft-like state and DOPC/40%
cholesterol existing in a non-raft-like state. The data in E, J, and M represent the averages of three independent experiments, and the error bars represent the
standard deviation. The data in A–D, F–I, and K–L are representative plots.

respectively). As shown in Fig. 3E, similarly to folded LtxA, the
affinity of LtxArenatured reached a maximum at 40% cholesterol
(minimum in KD); however, this maximum is less pronounced
(by 3 orders of magnitude) than the maximum affinity of native
LtxA for cholesterol-containing membranes (Fig. 2E) and is not
AUGUST 9, 2013 • VOLUME 288 • NUMBER 32

statistically significant. Table 3 shows the corresponding association (ka) and dissociation (kd) rates.
The extent of LtxA unfolding with GuHCl in the LtxArenatured
sample was analyzed by CD. As shown in the inset of Fig. 3E, the
CD spectra of LtxAwt (solid lines) indicated that the protein was
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folded and contained some secondary structure. In contrast,
the CD spectra of LtxAdenatured in 8 M GuHCl (dashed lines)
shows that the GuHCl has unfolded the protein. After GuHCl
exchange with liposome buffer, LtxArenatured (dotted lines)
adopted a similar, but distinct shape as LtxAwt, indicating that
the toxin remains partially unfolded. The final GuHCl concentration in the liposome buffer-exchanged sample was 2 M; previous work has shown that at this GuHCl concentration, LtxA
loses its ability to kill target cells (12). However, these results
suggest that the secondary structure of LtxA is not essential for
its binding to cholesterol.
LtxA Affinity for Cholesterol Is Independent of Its Acylation
Status—LtxA is post-translationally modified by the addition of
two fatty acid chains to two internal lysines (10). For some proteins, acylation has been proposed to enhance membrane association (34). We therefore investigated whether the association
of LtxA with cholesterol depends on the presence of the acyl
groups by using a nonacylated mutant (LtxACS001) and a reconstructed mutant (LtxASM003). The purity and cytotoxicity of
these mutants is shown in Fig. 1B and Table 1. We measured the
TABLE 3
Kinetic parameters of LtxAwt and LtxArenatured binding to liposomes
containing varying cholesterol compositions
LtxAwt or LtxArenatured was injected over liposomes composed of varying amounts of
cholesterol tethered to a L1 chip. The rates of association and dissociation (ka and kd,
respectively) were fit to a 1:1 Langmuir binding model, using the BIAevaluation
software. The values represent the means of four independent experiments ⫾
standard deviation.
ka
⫺1 ⫺1

kd

LtxAwt
0% cholesterol
20% cholesterol
40% cholesterol
60% cholesterol

s
7.68 ⫾ 4.38 ⫻ 104
7.32 ⫾ 1.63 ⫻ 104
6.05 ⫾ 0.88 ⫻ 104
6.31 ⫾ 1.43 ⫻ 104

s⫺1
7.51 ⫾ 3.95 ⫻ 10⫺4
3.10 ⫾ 2.26 ⫻ 10⫺4
3.00 ⫾ 2.59 ⫻ 10⫺7
3.10 ⫾ 3.09 ⫻ 10⫺5

LtxArenatured
0% cholesterol
20% cholesterol
40% cholesterol
60% cholesterol

7.39 ⫾ 3.27 ⫻ 104
6.68 ⫾ 2.24 ⫻ 104
6.33 ⫾ 3.10 ⫻ 104
3.76 ⫾ 1.82 ⫻ 104

1.54 ⫾ 1.01 ⫻ 10⫺3
1.53 ⫾ 0.03 ⫻ 10⫺4
5.48 ⫾ 2.47 ⫻ 10⫺5
9.37 ⫾ 3.83 ⫻ 10⫺5

M

binding of these mutant toxins to cholesterol using a steady
state SPR assay. The SPR sensorgrams are shown in Fig. 4A, and
the maximal response units (a measure of binding) are shown in
Fig. 4B. Binding to cholesterol was enhanced in the absence of
acyl chains, relative to the fully acylated protein, LtxASM003,
indicating that acylation is not responsible for the strong affinity of LtxA for cholesterol, and it may actually inhibit binding to
cholesterol.
LtxA Contains CRAC Sites—The high affinity binding of
LtxA to cholesterol suggests the presence of a lipid binding
site(s) within the LtxA protein. We scanned the LtxA amino
acid sequence of the toxin for the (L/V)X1–5YX1–5(R/K) CRAC
site motif (43), which has been shown to be associated with
cholesterol binding. We identified two putative CRAC sites
within the LtxA sequence: CRAC336 (333LEEYSKR339) and
CRAC503 (501VDYLK505) (Fig. 1A, yellow circles labeled C).
CRAC336 is located within the hydrophobic region and is highly
conserved among several RTX toxins, including E. coli HlyA,
M. hemolytica leukotoxin, Actinobacillus pleuropneumoniae
AppA, and A. pleuropneumoniae hemolysin (Table 4).
CRAC503 is not conserved with other RTX toxins, although
E. coli HlyA has some homology in that region. Bordetella pertussis adenylate cyclase toxin (CyaA) does not share either
CRAC motif with other RTX toxins, although the deduced
amino acid sequence does contain five putative CRAC sites.
CRAC Peptides Inhibit Cholesterol Binding by LtxA—Synthetic peptides corresponding to the CRAC336 and CRAC503
sequences were synthesized (Table 5). The first set of peptides
(CRAC336) corresponds to the CRAC site between residues 333
and 339, and the second set (CRAC503) corresponds to the
CRAC site between residues 501 and 505. Within each set, peptide “WT” is the wild type sequence, peptide “MUT” contains a
proline in place of the central tyrosine residue (the central tyrosine has been shown to be critical for cholesterol binding (44)),
and peptide “SCM” contains the scrambled CRAC sequence.

FIGURE 3. Affinity of LtxArenatured for cholesterol. Liposomes containing 0, 20, 40, or 60% cholesterol were tethered to an L1 Biacore chip, and LtxArenatured
was injected over the top. A–D, The sensorgrams show LtxArenatured binding to membranes containing 0% cholesterol (A), 20% cholesterol (B), 40% cholesterol
(C), and 60% cholesterol (D). E, the binding affinity (KD) of LtxArenatured was calculated from these sensorgrams. The CD spectra of LtxAwt (solid line), LtxAdenatured
in 8 M GuHCl (dashed lines), and LtxArenatured (dotted lines) in liposome buffer are shown in the inset of E. A one-way analysis of variance test indicates that there
is no significant difference in the data (p ⫽ 0.063). The data in E represent the averages of four independent experiments, and the error bars represent the
standard deviation. The data in A–D are representative plots.
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FIGURE 4. Effect of LtxA acylation on binding to cholesterol. Liposomes containing 40% cholesterol were tethered to an L1 Biacore chip, and acylated or
nonacylated LtxA was injected over the top. A, steady state SPR binding by nonacylated toxin (LtxACS001, solid line) and acylated toxin (LtxASM003, dashed line)
to liposomes containing 40% cholesterol. B, normalized response units (indicating extent of binding) at t ⫽ 2100 s for both protein types. The difference
between the two data points is not significant. The data in A and B represent the averages of three independent experiments, and the error bars represent the
standard deviation.

TABLE 4
RTX CRAC site homology

TABLE 6
Enthalpy of SOPC gel to liquid transition with 15 mol % peptide

Sequence homology of the two CRAC sites in LtxA with other RTX toxins. Each
CRAC site is bold and underlined.

Each of the six CRAC peptides was incubated with liposomes containing SOPC at 15
mol % peptide.

Toxin

Sequence

Peptide

MLEEYSKRFK341
QLESYSERFK329
334
SLESYAERFK343
330
LIKSYSERFQ339
330
QLEQYSERFK339
634
QLDKLAQESS643

None
CRAC336WT
CRAC336MUT
CRAC336SCM
CRAC503WT
CRAC503MUT
CRAC503SCM

Mutation

Tm

⌬Ha

°C

kcal/mol

None
Tyr 3 Pro
Scrambled
None
Tyr 3 Pro
Scrambled

3.7
3.6
3.6
3.6
3.7
3.7
3.7

4.00
4.00
4.18
4.25
4.13
3.40
3.49

336

CRAC
A. actinomycetemcomitans (LtxA)a
E. coli (HlyA)b
M. haemolytica (LktA)c
A. pleuropneumoniae (AppA)d
A. pleuropneumoniae (HlyA)e
B. pertussis (CyaA)f
CRAC503
A. actinomycetemcomitans (LtxA)a
E. coli (HlyA)b
M. haemolytica (LktA)c
A. pleuropneumoniae (AppA)d
A. pleuropneumoniae (HlyA)e
B. pertussis (CyaA)f

332

320

499

AYVDYLKKGE508
AYINYLENGG496
493
AYVDAFEEGQ502
497
AYVDAFEEGQ506
497
AYVDFFEEGK506
801
VFVDRFVQGE810
487

a

Sequence accession number CAA34731.
Sequence accession number AAC24352.
c
Sequence accession number Q9EV31.
d
Sequence accession number 123196.
e
Sequence accession number 1710793.
f
Sequence accession number 34978355.
b

TABLE 5
LtxA CRAC peptides
A panel of two sets of peptides was created to correspond to LtxA CRAC336 and
CRAC503 sequences. Each set contained peptides corresponding to the wild type
CRAC sequence (WT), the CRAC sequence with the Tyr replaced by Pro (MUT),
and the scrambled CRAC sequence (SCM).
Peptide

Mutation

Sequence

CRAC336WT
CRAC336MUT
CRAC336SCM
CRAC503WT
CRAC503MUT
CRAC503SCM

None
Tyr 3 Pro
Scrambled
None
Tyr 3 Pro
Scrambled

NH2-FDRARMLEEYSKRFKKFGY-OH
NH2-FDRARMLEEPSKRFKKFGY-OH
NH2-FDRARMYEKLERSFKKFGY-OH
NH2-QSGKAYVDYLKKGEELA-OH
NH2-QSGKAYVDPLKKGEELA-OH
NH2-QSGKAYYKLDVKGEELA-OH

The interaction of each of these peptides with cholesterolcontaining membranes was measured using DSC. The peptideinduced rearrangement of cholesterol in a membrane into cholesterol-rich domains can be followed by measuring the
formation of cholesterol crystallites when the sterol passes its
solubility limit. The formation of these crystallites can be readily detected with DSC through their polymorphic thermal transition, which occurs with a characteristic hysteresis, appearing
AUGUST 9, 2013 • VOLUME 288 • NUMBER 32

a

The transition temperature (Tm) and enthalpies (⌬H) were calculated as the
average from the cooling scans only (because the heating scans did not reach a
stable base line at low temperatures before the peak where heating was
initiated).

at ⬃35 °C in heating scans and at ⬃23 °C in cooling scans at
most conventional scan rates (45).
As shown in Table 6, none of the CRAC peptides caused a
change in the phase transition temperature of pure SOPC in the
absence of cholesterol at a peptide mol fraction of 0.15. In addition, none of the CRAC336 peptides caused any substantial
change in the gel to liquid crystalline phase transition enthalpy,
nor did CRAC peptide503WT. However, peptides CRAC503MUT
and CRAC503SCM both lowered the transition enthalpy by
⬃20%. Thus, two of the non-CRAC negative control peptides,
CRAC503MUT and CRAC503SCM, have some interaction with
SOPC, corresponding to a more hydrophobic peptide. However, by the DSC criterion, all of the other peptides have little
effect on the pure lipid, as shown in Fig. 5, and thus neither of
the CRAC peptides, CRAC336WT or CRAC503WT, penetrate
deeply into the bilayer in the absence of cholesterol.
With mixtures of SOPC and cholesterol at a molar ratio of
6:4, 15 mol % of each of the six peptides was used. No cholesterol crystallite transitions were observed in SOPC:cholesterol
6:4 in the absence of peptide, as observed by the absence of the
characteristic transitions at 35 °C on heating and at 23 °C on
cooling. In the presence of 15 mol % peptide, the characteristic
transitions were observed for all peptides, as shown in Table 7
and Fig. 6. The greatest enthalpies of these cholesterol crystallite transitions were observed with the two CRAC peptides,
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CRAC336WT and CRAC503WT (Table 7). These DSC results indicate that both CRAC peptides (CRAC336WT and CRAC503WT)
interact with cholesterol more strongly than do the control
peptides (CRAC336MUT, CRAC336SCM, CRAC503MUT, and
CRAC503SCM).
To determine whether the interaction of the CRAC peptides
with cholesterol inhibits binding of LtxA to cholesterol, a series
TABLE 7
Enthalpy of cholesterol crystallite transitions
Each of the six CRAC peptides was incubated with liposomes containing SOPC and
cholesterol (6:4) at 15 mol % peptide. The formation of cholesterol crystallites was
observed by the characteristic hysteresis at approximately 35 °C in heating scans and
at approximately 23 °C in cooling scans.

a

Peptide

Mutation

⌬Hheat

⌬Hcool

⌬Havga

cal/mol

cal/mol

cal/mol

CRAC336WT
CRAC336MUT
CRAC336SCM
CRAC503WT
CRAC503MUT
CRAC503SCM

None
Tyr 3 Pro
Scrambled
None
Tyr 3 Pro
Scrambled

160
100
80
190
95
60

140
80
60
170
75
60

150
90
70
180
85
60

The average transition enthalpies (⌬Havg) were calculated as the averages from
the heating and cooling scans.

of SPR competition experiments was run. In each experiment,
LtxA was incubated with increasing amounts of each CRAC
peptide (molar LtxA:peptide ratios of 1:0, 1:0.5, 1:1, 1:2, and
1:4), and this mixture was injected over tethered liposomes
containing 40% cholesterol.
Fig. 7A demonstrates that CRAC336WT inhibited binding of
LtxA to cholesterol. The CRAC336MUT (Fig. 7B) control peptide
only slightly inhibited binding of LtxA to cholesterol, and the
CRAC336SCM (Fig. 7C) control peptide slightly enhanced binding of LtxA to cholesterol. As shown in Fig. 7D, CRAC503WT
had a minimal effect on the binding of LtxA to cholesterol. The
CRAC503MUT peptide had an even slighter inhibitory effect on
binding, and CRAC503SCM slightly increased the binding of
LtxA to cholesterol, as shown in Fig. 7 (E and F, respectively).
The effects of all three CRAC503 peptides were statistically
insignificant (CRAC503WT, p ⬎ 0.096; CRAC503MUT, p ⬎ 0.284;
CRAC503SCM, p ⬎ 0.390). The hydrophobic nature of these six
peptides may have some effect on the binding of LtxA to the
membrane, but it is clear that the largest and most significant
effect is the inhibition of binding to cholesterol by CRAC336WT.

FIGURE 5. DSC scans showing the gel-to-liquid crystalline transition temperatures. Liposomes composed of 100% SOPC were mixed with 15 mol % CRAC
peptides. A, CRAC336WT; B, CRAC336MUT; C, CRAC336SCM; D, CRAC503WT; E, CRAC503MUT; F, CRAC503SCM. Positive curves are heating scans, and negative curves are
cooling scans. The curves were displaced along the y axis for ease of presentation. The scan rate was 1°/min.
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FIGURE 6. DSC scans showing the characteristic cholesterol crystallite transitions at 35 °C on heating and 23 °C on cooling. The lipid mixture was
SOPC:cholesterol 6:4, containing 15 mol % CRAC peptide. A, CRAC336WT; B, CRAC336MUT; C, CRAC336SCM; D, CRAC503WT; E, CRAC503MUT; F, CRAC503SCM. Positive
curves are heating scans, and negative curves are cooling scans. The curves were displaced along the y axis for ease of presentation. The scan rate was 1°/min.

Collectively, these results suggest that CRAC336 is involved in
the binding of cholesterol by LtxA, but CRAC503 is not. The
inhibition of binding by the CRAC336 and CRAC503 peptides is
shown in Fig. 7 (G and H, respectively).
In addition, the specificity of the inhibition of CRAC336WT
on binding to cholesterol was demonstrated by injecting the
LtxA/CRAC336WT mixtures over liposomes containing no cholesterol (100% DMPC). Here (Fig. 7I), no inhibition of binding
was observed, indicating that this peptide inhibits binding only
when cholesterol is present in the membrane, and therefore,
the peptide’s binding to cholesterol is what drives the observed
inhibition of LtxA binding.
LtxA Binding to Cholesterol Is Required for Cytotoxicity—The
effect of the CRAC peptides on the LtxA-mediated cytotoxicity
of Jn.9 cells was measured. Each set of cells was incubated for
5 h with either PBS, LtxA, LtxA:CRAC peptide (1:2), or CRAC
peptide alone.
Table 8 shows the % cytotoxicity values, normalized to LtxAinduced cytotoxicity, which was set as 1.00. CRAC336WT, which
inhibits LtxA binding to cholesterol, almost completely elimiAUGUST 9, 2013 • VOLUME 288 • NUMBER 32

nated LtxA-mediated cell death (% cytotoxicity ⫽ 0.06).
CRAC336MUT and CRAC336SCM, which do not inhibit LtxA
binding to cholesterol, had minimal effect on LtxA-mediated
cell death (% cytotoxicity ⫽ 0.97 and 0.98, respectively).
CRAC503WT, which only slightly inhibited LtxA binding to cholesterol, had no effect on LtxA-mediated cell death (% cytotoxicity ⫽ 1.03). The ability of each peptide to inhibit binding to
cholesterol by LtxA correlates with its inhibition of LtxA-mediated cytotoxicity, indicating that binding to cholesterol by the
toxin is a required step in its cytolysis.
CRAC336 Is Required for LtxA to Kill Target Cells—To confirm the in vitro binding studies that utilized CRAC peptides,
point mutations were induced in ltxA CRAC336 and CRAC503
sites to determine whether cholesterol binding affected LtxAmediated cytolysis in vivo. Using site-directed mutagenesis,
proline was substituted for tyrosine at amino acid positions 336
(for CRAC336) or 503 (for CRAC503) of individual ltxA. LtxAWT
and ltxA with the CRAC mutant genes were cloned into pSHH
and expressed in tandem with ltxC under the control of the wild
type leukotoxin promoter. Overnight cultures of LtxA and
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 7. Inhibition of LtxAwt binding to cholesterol-containing membranes by CRAC 1 and CRAC 2 peptides. A, CRAC336WT at ratios of 1:0, 1:0.5, 1:1, 1:2,
and 1:4 inhibits binding of LtxAwt to membranes containing 40% cholesterol. B and C, however, CRAC336MUT (B) and CRAC336SCM (C) at ratios of 1:0 1:0.5, 1:1, 1:2,
and 1:4 do not inhibit binding of LtxAwt to membranes containing 40% cholesterol. D, CRAC503WT at ratios of 1:0, 1:0.5, 1:1, 1:2, and 1:4 does not inhibit binding
of LtxAwt to membranes containing 40% cholesterol. E and F, likewise, CRAC503MUT (E) and CRAC503SCM (F) at ratios of 1:0, 1:0.5, 1:1, 1:2, and 1:4 do not inhibit
binding of LtxAwt to membranes containing 40% cholesterol. G, the CRAC336WT peptide inhibits LtxAwt binding to membranes containing 40% cholesterol
(black bars), but disruption of the CRAC site by changing Tyr to Pro (light gray bars, CRAC336MUT) or by scrambling the CRAC site (dark gray bars, CRAC336SCM)
prevents inhibition. H, the CRAC503 peptides (CRAC503WT, CRAC503MUT, and CRAC503SCM) do not inhibit LtxAwt binding to membranes containing 40% cholesterol. I, CRAC336WT at ratios of 1:0, 1:0.5, 1:1, 1:2, and 1:4 only slightly inhibits binding of LtxAwt to liposomes that do not contain cholesterol. The data represent
the averages of three experiments, and the error bars represent the standard deviation. **, p ⬍ 0.01; *, p ⬍ 0.05.

LtxA-CRAC mutants were constitutively expressed in the
E. coli DH5␣ cytosol and stained with rabbit anti-LtxA antibody (Fig. 8, insert). Following sonication, supernatants from
each experimental group and controls were normalized for protein content and incubated with Jn.9 target cells. The cytotoxicity was measured with a trypan blue cytotoxicity assay (32).
Jn.9 cells exposed to LtxAWT sonicates expressed in E. coli
had a reduced viability after 24 h of exposure (41.0 ⫾ 15.0%),
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when compared with a control sonicate that did not contain
ltxA (94.4 ⫾ 0.5%, p ⬍ 0.001). Cells exposed to the CRACY503P
mutant had a viability (49.7 ⫾ 19.3%, p ⫽ 0.02) that was only
slightly higher than cells exposed to wild type toxin. However,
the CRACY336P mutant was incapable of killing Jn.9 target cells
(87.7 ⫾ 3.3%, p ⫽ 0.04). These results indicate that an intact
CRAC336 site is required for LtxA toxicity, whereas the
CRAC503 site plays only a limited role in toxicity.
VOLUME 288 • NUMBER 32 • AUGUST 9, 2013
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TABLE 8
Inhibition of LtxA-mediated cytotoxicity by CRAC peptides
LtxA was preincubated with the CRAC peptides at a molar ratio of 1:2 before being
incubated with Jn.9 cells.
Toxin

Peptide mutation

Cytotoxicitya
% untreated control

None
LtxA
LtxA ⫹ CRAC336WT
LtxA ⫹ CRAC336MUT
LtxA ⫹ CRAC336SCM
LtxA ⫹ CRAC503WT
CRAC336WT alone
CRAC336MUT alone
CRAC336SCM alone
CRAC503WT alone
a

None
Tyr 3 Pro
Scrambled
None
None
Tyr 3 Pro
Scrambled
None

0.00
1.00
0.06 ⫾ 0.10
0.97 ⫾ 0.43
0.98 ⫾ 0.37
1.03 ⫾ 0.28
0.19 ⫾ 0.38
0.34 ⫾ 0.25
0.28 ⫾ 0.36
0.00 ⫾ 0.56

Cytotoxicity was measured using a trypan blue assay (32). The number of cells
killed under each experimental condition was normalized to the number of cells
killed by LtxA alone (after 5 h). Cytotoxicity was calculated as the number of
cells killed relative to an untreated control. Each value represents the mean of
three experiments ⫾ standard deviation.

FIGURE 8. Mutation of CRAC336 affects LtxA cytotoxicity. Point mutations
were induced in ltxA by substituting proline for tyrosine at amino acid positions 336 (for CRAC336) and 503 (for CRAC503), using site-directed mutagenesis. LtxA wild type and CRAC mutant genes were cloned into pSHH and
expressed in tandem with ltxC under the control of the native leukotoxin
promoter. The inset shows a Western blot of the cytosolic fractions of wild
type and CRAC mutants stained with anti-LtxA antibody. Overnight cultures
of LtxA and LtxA CRAC mutants were constitutively expressed in the E. coli
DH5␣ cytosol. Jn.9 cells were treated with 50 g of total protein from the
E. coli cytosolic fractions for 24 h. Jn.9 cells exposed to LtxAWT sonicates
expressed in E. coli had a reduced viability after 24 h of exposure (41.0 ⫾
15.0%) when compared with a control sonicate that did not contain ltxA
(94.4 ⫾ 0.5%, p ⬍ 0.001). A point mutation in ltxA that replaced Tyr336 with
Pro336 (CRACY336P) yielded a toxin mutant incapable of killing target cells
(87.7 ⫾ 3.3%, p ⫽ 0.04). On the other hand, whereas in vitro studies had
demonstrated the ability of CRAC503 to bind cholesterol, cells exposed to the
CRACY503P mutant had a viability (49.7 ⫾ 19.3%, p ⫽ 0.02) that was only
slightly higher than in cells exposed to wild type toxin. A sonicate from E. coli
DH5␣ containing the pSHH empty vector served as the negative control. Cell
death was measured with a trypan blue assay using a Vi-cell machine. ***, p ⬍
0.001; **, p ⬍ 0.05, relative to the empty vector control.

DISCUSSION
LtxA-induced raft clustering is dependent upon a toxin-induced increase in cytosolic Ca2⫹, activation of calpain, and
cleavage of talin, which allows mobilization to and subsequent
AUGUST 9, 2013 • VOLUME 288 • NUMBER 32

clustering of LtxA and its receptor, LFA-1, in lipid rafts (14).
Furthermore, other RTX toxins, such as a leukotoxin (Lkt) produced by M. hemolytica and the adenylate cyclase toxin (CyaA)
produced by B. pertussis, have been shown to have similar
effects on raft and receptor clustering (16, 47). Here, we
describe a unique mechanism of cholesterol binding by LtxA,
which we hypothesize to be involved in this previously reported
RTX/receptor clustering in lipid rafts.
Cholesterol-rich lipid rafts are dynamic and complex structures that admit or exclude certain proteins; as such, they provide platforms for signaling cascades (48). For example, LFA-1
clustering in lipid rafts plays several important roles in the
ontogeny of immune responses, such as the formation of an
immunological synapse (49, 50) or the arrest of immune cells on
endothelia expressing intercellular adhesion molecules (51). In
addition, cholesterol-rich lipid rafts play central roles in the
pathogenesis of various microorganisms in many different
ways, including docking, internalization, hiding, hijacking cell
signaling, and oligomerization (52–59). FimH-expressing
E. coli binds to the glycosylphosphatidylinositol-linked protein
CD48, which is located in lipid rafts, as a first step in internalization (56). Bacteria, including Campylobacter jejuni and
Mycobacterium bovis, as well as viruses are internalized in raftdependent processes (53–55, 58). A number of bacterial toxins,
including streptolysin O, Vibrio cholerae cytolysin, and anthrax
toxin, have been shown to use lipid rafts as a concentrating
platform for oligomerization (52, 59), whereas thiol-activated/
thiol-dependent streptolysins and listerolysin use raft lipids as
receptors (57).
The mechanism of lipid raft association and cholesterol
binding by LtxA appears to be distinct from these previously
reported mechanisms. We have shown that LtxA binds specifically to cholesterol-containing membranes in a unique mechanism with a strong cholesterol-dependent dissociation rate
but a cholesterol-independent association rate (Fig. 2). Two
regions of the deduced amino acid sequence of LtxA, 334LEEYSKR339 (CRAC336) and 502VDYLKK505 (CRAC503), were identified as potential cholesterol binding sites, based upon the
CRAC motif, (L/V)X1–5YX1–5(R/K) (60, 61). Although both
sites are juxtaposed to the LtxA hydrophobic domain, the
requirements for a CRAC motif are quite flexible, and therefore, not all predicted CRAC sites bind cholesterol or possess an
in vivo function. For this reason, we undertook an experimental
approach employing SPR and DSC with LtxA and synthetic
peptides corresponding to both CRAC336 and CRAC503 (Table
5). Our results indicate that LtxA binds cholesterol strongly,
and both CRAC peptides CRAC336WT and CRAC503WT also
interact strongly with cholesterol. However, only CRAC336WT
was able to inhibit binding of LtxA to cholesterol. CRAC503WT
and all of the control peptides had no effect on binding of LtxA
to cholesterol. In addition, only CRAC336WT, the only peptide
to inhibit binding to cholesterol, inhibited LtxA-mediated cytotoxicity. This behavior is consistent with our previous work, in
which we found that extraction of cholesterol from Jn.9 cells
inhibits LtxA-mediated cytotoxicity (14). In the panel of CRAC
mutants, modification of CRAC336 reduced the cytotoxicity of
LtxA, whereas modification of CRAC503 had only a limited
effect on the cytotoxicity of LtxA.
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FIGURE 9. Proposed mechanism of LtxA binding and resulting LFA-1/LtxA clustering in lipid rafts. In the absence of LtxA, LFA-1 moves transiently into and
out of lipid rafts (top panel). Binding of cholesterol by LtxA is almost irreversible, and therefore, transient movement of the LtxA䡠LFA-1 complex into the raft
becomes “permanent,” resulting in large LtxA䡠LFA-1 clusters in the lipid rafts (bottom panel).

Together, the results indicate that although both CRAC sites
may interact with cholesterol, the first CRAC site, CRAC336, is
responsible for cholesterol binding by LtxA. Interestingly, this
first CRAC site is highly conserved among RTX toxins, indicating that this mechanism may be common to other members of
this toxin family (Table 4). The second CRAC site, CRAC503,
which appears to have a less important role in cholesterol binding and cytotoxicity of LtxA, is less conserved among the RTX
toxins, appearing only in LtxA.
Our data indicate that cholesterol binding by LtxA is mediated by CRAC336; however, we could not rule out the possibility
that the acyl groups attached to LtxA could also be involved in
the process. For some proteins, acylation is required for membrane binding (62– 66); however, the role of acylation in the
RTX toxins has not yet been conclusively determined (34).
Studies have shown that acylation does not affect the ability of
E. coli ␣-HlyA to bind to either erythrocytes or liposomes (67,
68), but others have shown that acylation is involved in this
process (69 –71). Alternatively, acylation of the RTX toxins has
been proposed to be involved in protein-protein interactions or
pore formation (34, 68, 69, 72). Previously, we showed that the
acyl chains on LtxA are saturated and/or hydroxylated (10); this
hydroxylation may sterically inhibit association with cholesterolcontaining membranes, which are more tightly packed than
cholesterol-poor membranes. Acylation clearly plays a role in
cytotoxicity, because the nonacylated mutant was unable to kill
Jn.9 cells (Table 1); however, it appears that the role of acylation
in the cytotoxic mechanism is not the binding to cholesterol,
because there was no significant difference in the binding of
acylated LtxA (LtxAltxC/⫹ltxC) to cholesterol compared with
unacylated LtxA (LtxAltxC).
LtxA is not the only toxin produced by A. actinomycetemcomitans that binds to cholesterol using CRAC sequences. The
cytolethal distending toxin produced by this organism binds
membrane cholesterol before gaining access to the cytoplasm,
where it triggers cell cycle arrest (43). Surprisingly, although
both the A. actinomycetemcomitans-produced cytolethal dis-
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tending toxin and LtxA bind cholesterol via CRAC sites, the
mechanisms of binding of the toxins are quite different. The
affinity of the cytolethal distending toxin for cholesterol occurs
through an increased association rate when binding to cholesterol
and cholesterol-rich rafts (43), suggesting that the cytolethal distending toxin uses cholesterol as a receptor. Conversely, the affinity of LtxA for cholesterol is not dependent upon differences in
association rate (ka); rather, it is influenced by the cholesteroldependent change in dissociation rate (kd), suggesting that
LtxA is more indiscriminate in its binding, but once bound to
cholesterol, the attachment is almost irreversible.
The lipid compositions used in this work were specifically
chosen for their raft-forming nature. At room temperature, a
membrane composed of DMPC and 0% cholesterol exists in a
non-raft-like (liquid-disordered) phase, whereas at 40 and 60%
cholesterol, the membrane exists in a raft-like (liquid-ordered
phase) (27, 28). In vitro, the lipid composition of lipid rafts is
often ⬃30% (74 –77). The cholesterol compositions used in this
work are valid in both an in vitro and in vivo context.
Previous work in our lab found that LtxA is located in lipid
rafts only after it has bound to its receptor, LFA-1. Before the
binding of LtxA, LFA-1 is located outside of the raft, and upon
LtxA binding, the LtxA䡠LFA-1 complex moves to the raft, causing large scale clustering (14). Here, we demonstrated that the
association rate of LtxA to membranes does not change with
the cholesterol composition; in other words, LtxA does not
have a clear preference for binding to cholesterol, an observation that is consistent with this previous paper, in which LtxA
was found in both raft (cholesterol-rich) and non-raft (cholesterol-poor) regions of the membrane. Once LtxA binds to cholesterol, however, it remains tightly bound, providing a possible
mechanism for the observed LtxA䡠LFA-1 clustering in lipid
rafts (Fig. 9). Movement of proteins in and out of rafts is often
transient (23, 33, 46), and LFA-1 has been shown to reside in
two subsets: one within rafts and one outside (73). We hypothesize that LFA-1 is able to move into and out of rafts until it is
bound by LtxA, at which point, LtxA binds tightly to cholesVOLUME 288 • NUMBER 32 • AUGUST 9, 2013
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terol, holding the LtxA䡠LFA-1 complex in the raft and allowing
the formation of large clusters within the raft. Because we have
found that binding of LtxA to cholesterol is essential for LtxAmediated cell death, we propose that this cholesterol-dependent clustering is a key step in the cytotoxicity of LtxA.
The specific binding of other RTX toxins to cholesterol has
not been reported previously, although it has been shown that
both CyaA and Lkt cause a receptor/toxin clustering in lipid
rafts (16, 47). The mechanism of raft clustering by Lkt is similar
to what we have reported for LtxA; here, we have shown that
Lkt shares CRAC336 with LtxA, suggesting that the binding of
cholesterol by this RTX toxin may drive this receptor-dependent clustering in lipid rafts. However, CyaA, which does not
contain either of the two CRAC sites, has been shown to induce
the clustering of ␣M␤2 integrins in lipid rafts (47). The mechanism by which CyaA clusters in rafts differs slightly from the
mechanism used by LtxA (47); an interesting question will be
whether this difference in mechanism can be explained by the
lack of a CRAC site in CyaA or the fact that CyaA binds to a
different ␤2 integrin than does LtxA.
In this work, we have identified a unique but likely conserved
mechanism of cholesterol binding by a bacterial toxin. The
binding of cholesterol by LtxA occurs in an indirect fashion but
appears to regulate the cholesterol dependence of LtxA
cytotoxicity.
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